Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...